Novo Nordisk (NYSE:NVO) shares climbed more than 6% on Wednesday pre-market trading after the company reported solid first-quarter results, driven by robust demand for its diabetes and obesity treatments Warning! GuruFocus has detected 1 Warning Sign with NVO. First-quarter revenue rose 19% year-over-year, bolstered by a 21% increase in sales of diabetes and obesity care products. Wegovy, a key GLP-1 therapy, posted an 83% surge in global sales, while U.S. revenue grew 20% as the company anticipated improved supply in the second half of 2025, with compounded GLP-1 drugs being phased out. However, despite strong growth, Wegovy sales missed expectations, prompting the company to lower its full-year 2025 guidance. Novo Nordisk now expects sales to increase 13% to 21% for the year, down from a prior forecast of 18% to 26%. It also cut its operating profit growth forecast to 16% to 24% at constant exchange rates, down from an earlier estimate of 19% to 27%, citing slower-than-expected uptake of branded GLP-1 drugs in the U.S. The company also noted that currency effects could reduce reported growth by 3 to 5 percentage points, reflecting ongoing exchange rate volatility. Is Nova Nordisk a Buy After Earnings?Novo Nordisk Shares Jump 6% as Wegovy Fuels Double-Digit Growth Based on the one year price targets offered by 9 analysts, the average target price for Novo Nordisk AS is $95.44 with a high estimate of $127.32 and a low estimate of $63.96. The average target implies a upside of +43.97% from the current price of $66.29. Based on GuruFocus estimates, the GF Value for Novo Nordisk in one year is projected to be $158.09, implying a substantial upside of 138.48% from the current price of $66.29. This article first appeared on GuruFocus. View Comments
Novo Nordisk Shares Jump 6% as Wegovy Fuels Double-Digit Growth
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...